At a glance
ClinicalIndex Comparison RecordPhase 1Unknown· 18 target
Drug / intervention
IBR854 Cell Injectionbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of IBR854 Cell Injection in Patients With Unresectable Locally Advanced Or Metastatic Solid Tumors
In Brief
A Phase 1 clinical trial evaluating IBR854 Cell Injection for Solid Tumors. Targeting 18 participants across 1 site.
Detailed Summary
This study is an open-label, phase I study to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of IBR854 cell injection in patients with unresectable, locally advanced, or metastatic solid tumors.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSolid Tumors
CountriesChina
Collaborators--
Timeline
Phase 1UnknownOverdue
202420252026
First PostedAug 2023
Enrollment StartSep 2023
Primary CompletionSep 2024
Study CompletionDec 2024
TodayJul 2026
First PostedAug 21, 2023
Enrollment StartSep 1, 2023
Primary CompletionSep 30, 2024
Study CompletionDec 30, 2024
TodayJul 1, 2026
Enrollment to primary: 1.1 yearsPosted 2.9 years ago
Interventions
IBR854 Cell Injectionbiological
The minimum initial dose is 3.0×10\^9 cells and then escalate to 5.0×10\^9 cells and 7.0×10\^9 cells. Every 21 days is one cycle, and intravenous infusion is performed on day 1 and day 8 of each cycle.